20.52
Enliven Therapeutics Inc stock is traded at $20.52, with a volume of 208.83K.
It is down -0.15% in the last 24 hours and up +6.88% over the past month.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
See More
Previous Close:
$20.55
Open:
$20.75
24h Volume:
208.83K
Relative Volume:
0.45
Market Cap:
$1.21B
Revenue:
-
Net Income/Loss:
$-85.21M
P/E Ratio:
-10.86
EPS:
-1.89
Net Cash Flow:
$-68.53M
1W Performance:
-4.16%
1M Performance:
+6.88%
6M Performance:
+12.13%
1Y Performance:
-29.19%
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Name
Enliven Therapeutics Inc
Sector
Industry
Phone
720-647-8519
Address
6200 LOOKOUT ROAD, BOULDER
Compare ELVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
ELVN
Enliven Therapeutics Inc
|
20.51 | 1.22B | 0 | -85.21M | -68.53M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.77 | 109.29B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.25 | 60.82B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
579.50 | 61.02B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
810.58 | 51.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
309.94 | 34.68B | 4.56B | -176.77M | 225.30M | -1.7177 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Initiated | Goldman | Buy |
| Dec-13-24 | Initiated | BTIG Research | Buy |
| Sep-09-24 | Initiated | H.C. Wainwright | Buy |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-09-24 | Initiated | Mizuho | Buy |
| Mar-29-23 | Initiated | Jefferies | Buy |
View All
Enliven Therapeutics Inc Stock (ELVN) Latest News
Enliven Therapeutics Inc. recovery potential after sell offQuarterly Trade Summary & Daily Price Action Insights - newser.com
Is Enliven Therapeutics Inc. stock positioned well for digital economyWeekly Trade Recap & Stepwise Entry and Exit Trade Signals - newser.com
Applying sector rotation models to Enliven Therapeutics Inc.July 2025 Intraday Action & Free Fast Gain Swing Trade Alerts - newser.com
Is Enliven Therapeutics Inc. stock a safe haven asset2025 Earnings Surprises & Community Consensus Trade Alerts - newser.com
Why Enliven Therapeutics Inc. stock appeals to dividend seekersWeekly Profit Recap & Verified Trade Idea Suggestions - newser.com
Assessing Enliven Therapeutics (ELVN) Valuation as Shares Show Signs of Short-Term Momentum - Yahoo Finance
Real time breakdown of Enliven Therapeutics Inc. stock performanceEarnings Trend Report & Weekly High Return Forecasts - newser.com
Is Enliven Therapeutics Inc. stock cheap compared to fundamentalsFed Meeting & Target Return Focused Stock Picks - newser.com
Enliven Therapeutics Insider Sold Shares Worth $276,025, According to a Recent SEC Filing - MarketScreener
Published on: 2025-10-23 01:40:18 - newser.com
Lyssikatos, chief scientific officer, sells Enliven Therapeutics shares By Investing.com - Investing.com Canada
Brokerages Set Enliven Therapeutics, Inc. (NASDAQ:ELVN) Price Target at $41.20 - Defense World
Enliven Therapeutics CEO Kintz sells $266k in shares By Investing.com - Investing.com UK
ELVN insider sale: 12,500 shares sold; 902,892 shares remain held - Stock Titan
Is now a turning point for Enliven Therapeutics Inc.Global Markets & Risk Controlled Daily Plans - newser.com
Strategies to average down on Enliven Therapeutics Inc.Quarterly Profit Review & AI Powered Market Trend Analysis - newser.com
How to read the order book for Enliven Therapeutics Inc.2025 Institutional Moves & Verified Entry Point Signals - newser.com
Automated trading signals detected on Enliven Therapeutics Inc.Market Sentiment Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Trading Recap: Why retail investors favor Enliven Therapeutics Inc. stockEarnings Overview Summary & Verified Momentum Stock Watchlist - nchmf.gov.vn
Will Enliven Therapeutics Inc. stock rally after Fed decisions2025 Key Lessons & Real-Time Chart Pattern Alerts - nchmf.gov.vn
Will Enliven Therapeutics Inc. stock split again soon2025 Market WrapUp & Reliable Breakout Forecasts - nchmf.gov.vn
Will Enliven Therapeutics Inc. stock outperform tech sector in 2025July 2025 Institutional & Pattern Based Trade Signal System - nchmf.gov.vn
Heatmap analysis for Enliven Therapeutics Inc. and competitorsWatch List & Target Return Focused Picks - newser.com
Why retail investors favor Enliven Therapeutics Inc. stockWeekly Loss Report & Daily Profit Focused Screening - nchmf.gov.vn
Will Enliven Therapeutics Inc. stock continue dividend increases2025 Performance Recap & Daily Entry Point Trade Alerts - nchmf.gov.vn
(ELVN) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Enliven Therapeutics, Inc. (ELVN) Stock Analysis: Investor Outlook on a Potential 89.66% Upside - DirectorsTalk Interviews
Enliven Therapeutics (NASDAQ:ELVN) Trading 8.1% Higher – Time to Buy? - Defense World
Tools to monitor Enliven Therapeutics Inc. recovery probabilityRecession Risk & Daily Profit Maximizing Tips - newser.com
Published on: 2025-10-15 02:57:52 - newser.com
What the charts say about Enliven Therapeutics Inc. todayShort Setup & Daily Volume Surge Trade Alerts - newser.com
Enliven Therapeutics Inc Stock (ELVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Enliven Therapeutics Inc Stock (ELVN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kintz Samuel | PRESIDENT AND CEO |
Oct 17 '25 |
Sale |
21.33 |
12,500 |
266,654 |
902,892 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):